Low-dose preparative regimen and allogeneic stem cell transplantation in patients with multiple myeloma relapsing after autografting.

被引：0
|
作者：
Einsele, H
Bamberg, M
Schäfer, HJ
Hebart, H
Bader, P
Budach, W
Faul, C
Brugger, W
Kanz, L
机构：
[1] Dept Hematol & Oncol, Tubingen, Germany
[2] Dept Pediat, Tubingen, Germany
[3] Dept Radiotherapy, Tubingen, Germany
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4607
引用
收藏
页码：309B / 309B
页数：1
相关论文
共 50 条
  • [41] Disseminated toxoplasmosis after allogeneic stem cell transplantation for multiple myeloma
    Busemann, C.
    Ribback, S.
    Zimmermann, K.
    Seiler, V
    Kiefer, T.
    Schmidt, C. A.
    Dombrowski, F.
    Doelken, G.
    Krueger, W.
    ONKOLOGIE, 2010, 33 : 168 - 169
  • [42] Incidence of acute and chronic GvHD after low-dose Alemtuzumab- or ATG-containing conditioning regimen in patients with allogeneic stem cell transplantation
    Neumann, T.
    Busemann, C.
    Thiele, T.
    Pasewald, S.
    Klenner, A.
    Schulze, M.
    Doelken, G.
    Krueger, W. H.
    ONKOLOGIE, 2011, 34 : 282 - 283
  • [43] High-dose melphalan with BCNU and etoposide as preparative regimen for autologous hemopoietic stem cell transplantation in multiple myeloma (MM)
    Bernasconi, P
    Alessandrino, EP
    Colombo, AA
    Caldera, D
    Bonfichi, M
    Martinelli, G
    Malcovati, L
    Varettoni, M
    Maiocchi, M
    Brusamolino, E
    Pagnucco, G
    Castagnola, C
    Corso, A
    Bernasconi, C
    BONE MARROW TRANSPLANTATION, 1999, 23 : S133 - S133
  • [44] Thiotepa, fludarabine and melphalan, a reduced-dose regimen for allogeneic hematopoietic stem cell transplantation in multiple myeloma (MM)
    Severino, A
    Pescador, L
    Scime, R
    Corradini, P
    Narni, F
    Ruscio, C
    Gabriel-Arana, M
    Santoro, A
    De Blasio, A
    Locasciulli, A
    Majolino, I
    BONE MARROW TRANSPLANTATION, 2003, 31 : S158 - S158
  • [45] Thiotepa, fludarabine and melphalan, a reduced-dose regimen for allogeneic haematopoietic stem cell transplantation in multiple myeloma (MM).
    Majolino, I
    Severino, A
    Scimè, R
    Ruscio, C
    Tringali, S
    Sajeva, M
    Gabriel-Arana, M
    Tassone, C
    Pescador, L
    Blandino, F
    Santoro, A
    Locasciulli, A
    BLOOD, 2002, 100 (11) : 429B - 429B
  • [46] Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation
    Kroeger, Nicolaus
    Shimoni, Avichai
    Schilling, Georgia
    Schwerdtfeger, Rainer
    Bornhaueser, Martin
    Nagler, Arnon
    Zander, Axel R.
    Heinzelmann, Marion
    Brand, Ronald
    Gahrton, Gosta
    Morris, Curly
    Niederwieser, Dietger
    de Witte, Theo
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 148 (02) : 323 - 331
  • [47] Dose Finding Study of Lenalidomide as Maintenance Therapy In Multiple Myeloma After Allogeneic Stem Cell Transplantation
    Wolschke, Christine
    Schonland, Stefan O.
    Hegenbart, Ute
    Stuebig, Thomas
    Heinzelmann, Marion
    Hildebrandt, York
    Lioznov, Michael
    Zander, Axel R.
    Kroeger, Nicolaus
    BLOOD, 2010, 116 (21) : 984 - 984
  • [48] Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma
    (Zhang XH
    中华医学杂志(英文版), 2007, (06) : 463 - 468
  • [49] Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma
    Zhang XHHuang XJLiu KYXu LPLiu DHChen HChen YHWang JZHan W and Lu DPInstitute of HematologyPeking University Peoples HospitalBeijing China
    ChineseMedicalJournal, 2007, 120 (06) : 463 - 468
  • [50] Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma
    Zhang Xiao-hui
    Huang Xiao-jun
    Liu Kai-yan
    Xu Lan-ping
    Liu Dai-hong
    Chen Huan
    Chen Yu-hong
    Wang Jing-zhi
    Han Wei
    Lu Dao-pei
    CHINESE MEDICAL JOURNAL, 2007, 120 (06) : 463 - 468
12345